

Radicava ORS - (105 mg/5 mL; Oral Suspension)

Generic Name	Edaravone	Innovator	Mitsubishi Tanabe
Dosage	105 mg/5 mL; Oral Suspension	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	RADICAVA ORS is indicated for the treatment of amyotrophic lateral sclerosis (ALS)		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.